GAMMA Investing LLC Reduces Holdings in Jazz Pharmaceuticals PLC $JAZZ

GAMMA Investing LLC decreased its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 50.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 501 shares of the specialty pharmaceutical company’s stock after selling 514 shares during the period. GAMMA Investing LLC’s holdings in Jazz Pharmaceuticals were worth $53,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in JAZZ. Hurley Capital LLC acquired a new position in Jazz Pharmaceuticals in the 1st quarter worth $25,000. Parallel Advisors LLC increased its position in shares of Jazz Pharmaceuticals by 85.6% during the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company’s stock worth $32,000 after acquiring an additional 119 shares during the last quarter. Picton Mahoney Asset Management increased its position in shares of Jazz Pharmaceuticals by 2,445.5% during the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock worth $34,000 after acquiring an additional 269 shares during the last quarter. Spire Wealth Management increased its position in shares of Jazz Pharmaceuticals by 137.6% during the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company’s stock worth $35,000 after acquiring an additional 161 shares during the last quarter. Finally, SVB Wealth LLC purchased a new stake in shares of Jazz Pharmaceuticals during the first quarter worth about $36,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on JAZZ shares. Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Weiss Ratings restated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research note on Saturday, September 27th. Royal Bank Of Canada boosted their target price on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an “outperform” rating in a research report on Thursday, August 28th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Finally, The Goldman Sachs Group boosted their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a research report on Friday, August 29th. Fourteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $178.93.

Insider Activity

In related news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the completion of the sale, the director directly owned 429,973 shares in the company, valued at approximately $55,303,127.26. This trade represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last 90 days, insiders have sold 11,500 shares of company stock valued at $1,525,280. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Stock Up 1.7%

Shares of JAZZ stock opened at $139.48 on Friday. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The stock has a market cap of $8.46 billion, a PE ratio of -20.73, a price-to-earnings-growth ratio of 8.65 and a beta of 0.28. The business’s fifty day moving average is $123.75 and its 200-day moving average is $115.66. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same quarter last year, the business posted $5.30 earnings per share. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.